PT Darya-Varia Laboratoria Tbk (DVLA.JK)
IDR 1490.0
(2.76%)
IDR 1490.0
(2.76%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 146.33 Billion IDR | -2.03% |
| 2022 | 149.37 Billion IDR | 1.96% |
| 2021 | 146.5 Billion IDR | -9.61% |
| 2020 | 162.07 Billion IDR | -26.92% |
| 2019 | 221.78 Billion IDR | 10.53% |
| 2018 | 200.65 Billion IDR | 23.67% |
| 2017 | 162.24 Billion IDR | 6.68% |
| 2016 | 152.08 Billion IDR | 40.96% |
| 2015 | 107.89 Billion IDR | 33.32% |
| 2014 | 80.92 Billion IDR | -35.67% |
| 2013 | 125.79 Billion IDR | -15.52% |
| 2012 | 148.9 Billion IDR | 23.15% |
| 2011 | 120.91 Billion IDR | 9.05% |
| 2010 | 110.88 Billion IDR | 53.42% |
| 2009 | 72.27 Billion IDR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 67.48 Billion IDR | 45.08% |
| 2024 Q3 | 28.03 Billion IDR | -45.96% |
| 2024 Q2 | 51.86 Billion IDR | -23.15% |
| 2023 Q4 | 46.51 Billion IDR | 1226.63% |
| 2023 FY | 146.33 Billion IDR | -2.03% |
| 2023 Q1 | 60.91 Billion IDR | 482.68% |
| 2023 Q2 | 35.39 Billion IDR | -41.89% |
| 2023 Q3 | 3.5 Billion IDR | -90.09% |
| 2022 Q4 | -15.91 Billion IDR | -293.93% |
| 2022 Q1 | 137.01 Billion IDR | 212.92% |
| 2022 Q2 | 32.31 Billion IDR | -76.41% |
| 2022 FY | 149.37 Billion IDR | 1.96% |
| 2022 Q3 | -4.04 Billion IDR | -112.5% |
| 2021 Q4 | -121.33 Billion IDR | -190.05% |
| 2021 FY | 146.5 Billion IDR | -9.61% |
| 2021 Q1 | 80.92 Billion IDR | 447.55% |
| 2021 Q2 | 52.39 Billion IDR | -35.25% |
| 2021 Q3 | 134.74 Billion IDR | 157.17% |
| 2020 Q1 | 56.48 Billion IDR | 27.77% |
| 2020 Q4 | 14.77 Billion IDR | 77.47% |
| 2020 Q3 | 8.32 Billion IDR | -89.9% |
| 2020 FY | 162.07 Billion IDR | -26.92% |
| 2020 Q2 | 82.48 Billion IDR | 46.04% |
| 2019 Q3 | 63.8 Billion IDR | 108.75% |
| 2019 Q1 | 83.2 Billion IDR | 122.43% |
| 2019 Q2 | 30.56 Billion IDR | -63.27% |
| 2019 FY | 221.78 Billion IDR | 10.53% |
| 2019 Q4 | 44.2 Billion IDR | -30.72% |
| 2018 FY | 200.65 Billion IDR | 23.67% |
| 2018 Q4 | 37.4 Billion IDR | -31.9% |
| 2018 Q3 | 54.93 Billion IDR | 20.85% |
| 2018 Q2 | 45.45 Billion IDR | -27.68% |
| 2018 Q1 | 62.85 Billion IDR | 720.48% |
| 2017 Q2 | 37.5 Billion IDR | -55.13% |
| 2017 Q3 | 51.3 Billion IDR | 36.8% |
| 2017 Q1 | 83.57 Billion IDR | 468.83% |
| 2017 FY | 162.24 Billion IDR | 6.68% |
| 2017 Q4 | -10.12 Billion IDR | -119.75% |
| 2016 Q2 | 26.82 Billion IDR | -52.58% |
| 2016 Q4 | 14.69 Billion IDR | -72.78% |
| 2016 FY | 152.08 Billion IDR | 40.96% |
| 2016 Q1 | 56.57 Billion IDR | 457.86% |
| 2016 Q3 | 53.98 Billion IDR | 101.22% |
| 2015 Q3 | 20.44 Billion IDR | 17.04% |
| 2015 FY | 107.89 Billion IDR | 33.32% |
| 2015 Q1 | 59.84 Billion IDR | 1842.89% |
| 2015 Q2 | 17.46 Billion IDR | -70.81% |
| 2015 Q4 | 10.14 Billion IDR | -50.39% |
| 2014 Q1 | -17.41 Billion IDR | -156.74% |
| 2014 FY | 80.92 Billion IDR | -35.67% |
| 2014 Q4 | 3.07 Billion IDR | -88.85% |
| 2014 Q3 | 27.61 Billion IDR | -59.19% |
| 2014 Q2 | 67.65 Billion IDR | 488.4% |
| 2013 Q3 | 16.45 Billion IDR | -52.8% |
| 2013 Q1 | 43.79 Billion IDR | 9.18% |
| 2013 FY | 125.79 Billion IDR | -15.52% |
| 2013 Q4 | 30.7 Billion IDR | 86.64% |
| 2013 Q2 | 34.85 Billion IDR | -20.42% |
| 2012 Q3 | 25.9 Billion IDR | 0.0% |
| 2012 FY | 148.9 Billion IDR | 23.15% |
| 2012 Q4 | 40.11 Billion IDR | 54.81% |
| 2011 FY | 120.91 Billion IDR | 9.05% |
| 2010 FY | 110.88 Billion IDR | 53.42% |
| 2009 FY | 72.27 Billion IDR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| PT Merck Tbk | 178.24 Billion IDR | 17.899% |
| PT Phapros, Tbk | 5.95 Billion IDR | -2355.585% |
| PT Pyridam Farma Tbk | -85.22 Billion IDR | 271.714% |
| PT Industri Jamu dan Farmasi Sido Muncul Tbk | 950.64 Billion IDR | 84.607% |
| PT Tempo Scan Pacific Tbk | 1177.43 Billion IDR | 87.572% |